Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

Fig. 4

Changes in tumor mutation burden and copy number following PIKTOR treatment. (A) Individual fraction copy number-altered genome values for pre- and post- PIKTOR biopsies. Patient ID is labeled on right. (B) Percent change in fraction copy number-altered genome from (A). Boxplot shows median and upper and lower quartiles, as well as the highest and lowest values represented by error bars. Each patient is labeled with their identifier. (C) Individual tumor mutation burden per million bases for pre- and post- PIKTOR biopsies. Patient ID is labeled on right. (D) Percent change tumor mutation burden from (C). Boxplot shows median and upper and lower quartiles, as well as the highest and lowest values represented by error bars. Each patient is labeled with their identifier

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us